PT  - JOURNAL ARTICLE
AU  - Singh, Prajjval Pratap
AU  - Tamang, Rakesh
AU  - Shukla, Manoj
AU  - Pathak, Abhishek
AU  - Srivastava, Anshika
AU  - Gupta, Pranav
AU  - Bhatt, Alay
AU  - Shrivastava, Abhishek K.
AU  - Upadhyay, Sudhir K.
AU  - Singh, Ashish
AU  - Maurya, Sanjeev
AU  - Saxena, Purnendu
AU  - Singh, Vanya
AU  - Chaubey, Akhilesh Kumar
AU  - Mishra, Dinesh Kumar
AU  - Patel, Yashvant
AU  - Pandey, Rudra Kumar
AU  - Srivastava, Ankit
AU  - Khanam, Nargis
AU  - Das, Debashruti
AU  - Bandopadhyay, Audditiya
AU  - Chorol, Urgyan
AU  - Pasupuleti, Nagarjuna
AU  - Kumar, Sachin
AU  - Prakash, Satya
AU  - Mishra, Astha
AU  - Dubey, Pavan Kumar
AU  - Parihar, Ajit
AU  - Basu, Priyoneel
AU  - Sequeira, Jaison J
AU  - KC, Lavanya
AU  - Vijayalaxmi, Vijayalaxmi
AU  - Bhat.K, Vishnu Shreekara
AU  - Ijinu, Thadiyan Parambil
AU  - Aggarwal, Dau Dayal
AU  - Prakash, Anand
AU  - Yadav, Kiran
AU  - Yadav, Anupam
AU  - Upadhyay, Vandana
AU  - Mukim, Gunjan
AU  - Bhandari, Ankan
AU  - Ghosh, Ankita
AU  - Kumar, Akash
AU  - Yadav, Vijay Kumar
AU  - Nigam, Kriti
AU  - Harshey, Abhimanyu
AU  - Das, Tanurup
AU  - Devadas, Deepa
AU  - Mishra, Surendra Pratap
AU  - Kumar, Ashish
AU  - Yadav, Abhay Kumar
AU  - Singh, Nitish Kumar
AU  - Kaur, Manpreet
AU  - Kumar, Sanjay
AU  - Srivastava, Nikhil
AU  - Sharma, Charu
AU  - Chowdhury, Ritabrata
AU  - Jain, Dharmendra
AU  - Kumar, Abhai
AU  - Shukla, Ritesh
AU  - Mishra, Raghav Kumar
AU  - Singh, Royana
AU  - Tripathi, Yamini B
AU  - Mishra, Vijay Nath
AU  - Mustak, Mohammed S.
AU  - Rai, Niraj
AU  - Rawat, Sumit Kumar
AU  - Survajhala, Prashant
AU  - singh, Keshav K
AU  - Mallick, Chandana Basu
AU  - Shrivastava, Pankaj
AU  - Chaubey, Gyaneshwer
TI  - Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations
AID  - 10.1101/2021.02.05.21251118
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.05.21251118
4099  - http://medrxiv.org/content/early/2021/04/10/2021.02.05.21251118.short
4100  - http://medrxiv.org/content/early/2021/04/10/2021.02.05.21251118.full
AB  - Infection born by Coronavirus SARS-CoV-2 has swept the world within a time of a few months. It has created a devastating effect on humanity with social and economic depression. Europe and America were the hardest hit continents. India has also lost lives, making the country fourth most deadly worldwide. However, the infection and death rate per million and the case fatality ratio in India were substantially lower than in many developed nations. Several factors have been proposed including genetics. One of the important facts is that a large chunk of Indian population is asymptomatic to the SARS-CoV-2 infection. Thus, the real infection in India is much higher than the reported number of cases. Therefore, the majority of people are already immune in the country. To understand the dynamics of real infection as well as the level of immunity against SARS-CoV-2, we have performed antibody testing (serosurveillance) in the urban region of fourteen Indian districts encompassing six states. In our survey, the seroprevalence frequency varied between 0.01-0.48, suggesting high variability of viral transmission between states. We also found out that the cases reported by the government were several fold lower than the real incidence of infection. This discrepancy is mainly driven by the higher number of asymptomatic cases. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of the districts, the case fatality rate of second wave in India will be minor than first wave.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding rceived for this specific work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is approved by the Ethical committe of Banaras Hindu University, Varanasi, IndiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available with the manuscript.